Inhibition of 5-lipoxygenase: development of hydroxamic acids and hydroxyureas as potential therapeutic agents.
Salmon
J A
JA
Wellcome Research Laboratories, Beckenham, Kent, U.K.
Jackson
W P
WP
Garland
L G
LG
D000284:Administration, Oral; D000818:Animals; D044482:Benzeneacetamides; D001682:Biological Availability; D001711:Biotransformation; D000001:Calcimycin / Q000494:pharmacology; D004285:Dogs; D015195:Drug Design; D006207:Half-Life; D006801:Humans; D006877:Hydroxamic Acids / Q000493:pharmacokinetics / Q000494:pharmacology*; D006918:Hydroxyurea / Q000493:pharmacokinetics / Q000494:pharmacology*; D007975:Leukotriene B4 / Q000096:biosynthesis; D016859:Lipoxygenase Inhibitors; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D011817:Rabbits; D051381:Rats; D013329:Structure-Activity Relationship
D044482:Benzeneacetamides; D006877:Hydroxamic Acids; D016859:Lipoxygenase Inhibitors; C056614:N-(3-phenoxycinnamyl)acetohydroxamic acid; D007975:Leukotriene B4; D000001:Calcimycin; D006918:Hydroxyurea